Bond Screener
AstraZeneca
LEI PY6ZZQWO2IZFZC3IOL08
Organization name
Astrazeneca Plc
Country name
United Kingdom
Country of registration
United Kingdom
Industry
Pharmaceutical Preparation and Biotechnology
Credit Ratings
in foreign currency
Public debt
20,464 mln USD
New to Cbonds? · Take a 90-second tour of the platform.
Discover what you can do with Cbonds
Everything you need for fixed income research and monitoring.
- 00:23 Coverage
- 00:40 Bond screener
- 00:54 Parameters
- 01:10 Watchlist, Mobile app
- 01:15 Excel Add-in
Trading Schedule Issuer map
Quotes
/
/
/
pcs.
pcs.
pcs.
- «
- 1
- ...
- {{ quotes.page - 2 }}
- {{ quotes.page - 1 }}
- {{ quotes.page }}
- {{ quotes.page + 1 }}
- {{ quotes.page + 2 }}
- ...
- {{ quotesLastPage }}
- »
Quotes provided by information providers are indicative in nature
Profile
|
AstraZeneca PLC operates as a holding company. The Company, through its subsidiaries, researches, manufactures, and sells pharmaceutical and medical products. AstraZeneca focuses its operations on eight therapeutic areas, including gastrointestinal, oncology, cardiovascular, respiratory, central nervous system, pain control, anaesthesia, and infection.
|
General information
-
Organization nameAstrazeneca Plc
-
Organization statusOperating organization
-
Address1 Francis Crick Avenue Cambridge Biomedical Campus Cambridge, United Kingdom, CB2 0AA
-
Site
-
IR Site
News
-
New issues: AstraZeneca issued international bonds (XS3484302461, XS3484302545, XS3484302628) in the amount of EUR 600, EUR 500, EUR 750 mln maturing in 2032, 2035, 2038 respectively.25/08/2026
-
New issue: AstraZeneca issued international bonds (XS3484302206) with the coupon rate of 3.402% in the amount of EUR 700 mln maturing in 203025/08/2026
-
Daiichi Sankyo And AstraZeneca's Phase 3 Trial Enhertu Meets Primary Endpoint In HER2 NSCLC17/08/2026
-
AstraZeneca Discontinues Phase 3 EVOLVE-Lung02 Trial Of Volrustomig In Non-small Cell Lung Cancer17/08/2026
-
Are Mega-Mergers Back?15/08/2026
IFRS/US GAAP reports
| 2026 | |
| 2025 | |
| 2024 | |
| 2023 | |
| 2022 | |
| 2021 | |
| 2020 | |
| 2019 | |
| 2018 | |
| 2017 | |
Show more
Hide
Authorization required
You need to request access
Stocks
General information
-
Organization nameAstrazeneca Plc
-
Organization statusOperating organization
-
Address1 Francis Crick Avenue Cambridge Biomedical Campus Cambridge, United Kingdom, CB2 0AA
-
Site
-
IR Site
Codes
-
LEIPY6ZZQWO2IZFZC3IOL08
-
SIC2834 PHARMACEUTICAL PREPARATIONS
-
ICB4,500 Health Care
-
NACE*** ***
-
NAICS*** ***
-
CIK0000901832
